期刊
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
卷 30, 期 2, 页码 523-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2016.02.011
关键词
Aminoglycoside; 16S ribosomal RNA; Posttranscriptional methylation; Carbapenemease
资金
- National Institutes of Health [R01AI104895, R21AI107302, R21AI123747]
Aminoglycoside-producing Actinobacteria are known to protect themselves from their own aminoglycoside metabolites by producing 16S ribosomal RNA methyltransferase (16S-RMTase), which prevents them from binding to the 16S rRNA targets. Ten acquired 16S-RMTases have been reported from gram-negative pathogens. Most of them posttranscriptionally methylate residue G1405 of 16S rRNA resulting in high-level resistance to gentamicin, tobramycin, amikacin, and plazomicin. Strains that produce 16S-RMTase are frequently multidrug-resistant or even extensively drug resistant. Although the direct clinical impact of high-level aminoglycoside resistance resulting from production of 16S-RMTase is yet to be determined, ongoing spread of this mechanism will further limit treatment options for multidrug-resistant and extensively drug-resistant gram-negative infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据